25 September 2018
Visiongain has launched a new pharma report: Global Next-Generation Antibody Therapies Market Forecast 2018-2028: Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies.
Next-generation antibody therapies are becoming established treatments for haematological malignancies and solid tumours (phase 3) pipelines are relatively sparse, however, with most pipeline candidates in phase 1 or phase 2 of development. Growth will be rapid from the middle of the forecast period as new therapies are approved. New therapies will likely compete with currently marketed monoclonal antibodies, biosimilars, and novel small molecule drugs. Increasing collaboration between biotechnology and big pharma companies will drive pipeline development, which may result in the dominance of a small number of technology platforms, as seen for example in the market for antibody-drug conjugates.
The lead analyst of the report commented "Success for developers of next-generation antibody therapies will depend on a number of factors, including having a technology platform that offers some advantage over standard monoclonal antibodies, the ability to advance a novel therapy through proof of concept, and partnership opportunities with Big Pharma.
Products that offer superior or additional efficacy compared to currently available therapies will be needed in order to compete against existing therapies and the biosimilars that are expected to become available for these therapies in developed markets. Alternatively, targeting new indications and new antigens will expand the potential in the market."
Leading companies featured in the report include Amgen, Inc., GlaxoSmithKline (GSK), Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.), Merck KGaA, Novartis AG, Pfizer, Inc., Roche, Sanofi, Seattle Genetics, Inc., Shire plc
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.
05 July 2019
Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.
28 June 2019
Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.
25 June 2019
Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.